Visão geral da empresa
Aeon Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of botulinum toxins for the treatment of debilitating medical conditions. The company's primary focus is on advancing ABP-450, a formulation of prabotulinumtoxinA, which has successfully completed Phase 2 studies for cervical dystonia and currently maintains an ongoing Phase 2 study for other indications. Within the broader financial landscape, the firm is categorized under the Healthcare sector and specifically within the Biotechnology industry, an environment characterized by high capital requirements and significant research and development risks. The organization maintains a market capitalization of $21.00M and employs a workforce of 8 individuals to execute its strategic initiatives. These valuation figures and operational scale indicate that Aeon Biopharma is a micro-cap enterprise with limited resources, operating without the revenue base typical of mature pharmaceutical firms, which necessitates a reliance on external financing or future milestone payments to sustain its clinical development pipeline.
Saúde financeira
The company reports a Net Income of $-39,222,000 and an EBITDA of $-16,224,000 over the trailing twelve-month period, while Revenue data is not available in the provided financial records. The substantial negative gap between revenue and net income, alongside the negative EBITDA, reveals a cost structure dominated by non-operating expenses or significant interest costs that outweigh any operational earnings before interest and taxes. Free Cash Flow stands at $-10,995,750, indicating a continuous consumption of cash reserves rather than generation of liquidity, which limits the company's financial flexibility to fund operations without further capital raises. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, suggesting that the company either has no recognized revenue in the reporting period or that its current financial structure results in zero profitability across all levels of operation. In terms of leverage, the company holds $3.01M in cash against $35.74M in total debt, resulting in a Debt to Equity ratio that is not calculable due to lack of equity data, but the absolute debt load significantly exceeds available liquid assets. The Current Ratio is 0.49, which indicates that the company's current assets are insufficient to cover its current liabilities without additional financing or asset liquidation. Return on Equity is not available for calculation, while Return on Assets is -234.2%, a metric that reveals management is utilizing the company's asset base to generate substantial losses rather than positive returns.
Avaliação de valorização
Valuation multiples for Aeon Biopharma present a complex picture, with a Trailing Twelve Month P/E Ratio listed as N/A due to negative earnings and a Forward P/E of -1.20, which implies that the market is pricing the stock based on future expectations that do not yet reflect positive profitability. The Price to Book ratio is -0.18, a figure that technically indicates the market price is below the book value in a negative sense, often seen in companies with significant intangible assets or accumulated deficits that distort traditional book value calculations. Price to Sales and EV/EBITDA multiples are recorded as N/A and -3.31 respectively; the negative EV/EBITDA suggests that the company's enterprise value exceeds its earnings before interest, taxes, depreciation, and amortization, a common characteristic of pre-revenue biotech firms relying on debt financing. The stock has demonstrated significant volatility over the past year, trading between a 52-Week Low of $0.38 and a 52-Week High of $1.45. Relative to this range, the current trading position fluctuates within a band that represents more than 70% of the distance between the low and high, reflecting the speculative nature of its valuation. The Beta is 0.73, indicating that the stock's price volatility is approximately 27% lower than the broader market average, which may offer some relative stability despite the company's fundamental financial distress.
Growth & Income
Growth metrics for revenue and earnings are both listed as N/A, which precludes a direct comparison of earnings growth rates against revenue growth in terms of percentage expansion. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the firm retains all available cash, albeit negative, to fund its ongoing operations and clinical trials rather than distributing income to shareholders. The absence of a dividend policy is consistent with the capital-intensive nature of the biotechnology industry, where companies typically reinvest earnings into research, development, and clinical trials to achieve commercialization milestones. Consequently, the overall growth and income profile of Aeon Biopharma is defined entirely by its potential for future commercialization of ABP-450, as it currently lacks historical growth data and does not provide income through dividends, leaving shareholder returns contingent solely on capital appreciation or a potential future exit event.